Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.98 as of 2026-09-12T00:15:46.919Z.
Consensus retrieved: 2026-09-11T03:01:11.262Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:15:46.919Z.
Quote observation: 2026-09-11T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 21d4530f46c27a330a27e13acc83cdd67f4baeb56c07e52c66d3cc6e0046e444
Forward PE Ratio (16.98) = Dated Quote Price ($311.54) / Consensus Forward EPS ($18.35)
FORWARD PE RATIO
16.98
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-10.42%
vs the sector median at left
Labcorp Holdings Inc.
Market Cap
$25.55B
Forward PE Ratio
16.98
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Labcorp Holdings Inc. (LH) | $25.55B | 16.98 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 21.00 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.14B | 27.33 |
| Incyte Corporation (INCY)vs › | $24.62B | 32.29 |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 38.61 |
| BioNTech SE (BNTX)vs › | $24.30B | N/A |
| Medline Inc. (MDLN)vs › | $27.51B | 21.79 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $28.88B | 12.98 |
| United Therapeutics Corporation (UTHR)vs › | $21.10B | 19.01 |
| Waters Corporation (WAT)vs › | $30.54B | 28.02 |
Trailing P/E
25.8
reported TTM EPS
Forward P/E
17.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $18.35 implies +51.8% EPS growth vs the reported trailing $12.09.
At the dated quote price of $311.54, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $18.35 | $18.13 – $18.46 | 10 | 17.0x |
| 2027-12-31 | $19.88 | $18.91 – $20.31 | 12 | 15.7x |
| 2028-12-31 | $21.58 | $19.41 – $24.43 | 8 | 14.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
